Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914609 · ClinicalTrials.gov registry record · Phase 3
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
A Phase 3 study of Angelman Syndrome, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT06914609: Recruiting Phase 3 study of Angelman Syndrome, sponsored by Ionis Pharmaceuticals.
NCT06914609 is a Phase 3 study of Angelman Syndrome that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 158 participants, above the 112-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06914609, a Phase 3 study of Angelman Syndrome, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Primary Outcome
The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The expressive communication subdomain of communication measures preverbal and verbal communication. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater expressive communication ability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ION582
Study Locations (20)
Other
- Perth Children's Hospital - Nedlands
- Sydney Children's Hospital - Randwick
- University of Alberta Hospital - Edmonton
California
- Cedars-Sinai Medical Center - Los Angeles
- Rady Children's Hospital - San Diego
Colorado
- Colorado Children's Hospital Research Institute - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Children's Mercy - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2030-04 |
| Phase | Phase 3 |
What NCT06914609 shows while recruiting
NCT06914609 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (41% higher).
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06914609 names 20 study sites across 17 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06914609 about?
NCT06914609 is a clinical study titled "REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome". The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
What is the current status of trial NCT06914609?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2025-06-10. Estimated completion is 2030-04.
What conditions does trial NCT06914609 study?
This clinical trial studies the following conditions: Angelman Syndrome.
What interventions are being tested in trial NCT06914609?
The interventions under investigation include: Placebo (DRUG), ION582 (DRUG).
Who is sponsoring clinical trial NCT06914609?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914609 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06914609's enrollment target sits among peer trials
158 3rd of 11 higher than 9 of 11 other Angelman Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Angelman Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
ACTIVE NOT RECRUITING · Phase 3
-
Angelman Syndrome Natural History Study
RECRUITING
-
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITING · Phase 1
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI